Cost-effectiveness of therapies for melanoma

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 2, 2015, Pages 229-242

  Johnston, Karissa M ^a   Mcpherson, Emily ^b   Osenenko, Katherine ^a   Vergidis, Joanna ^c   Levy, Adrian R ^a,d   Peacock, Stuart ^b,e  

^a ICON Epidemiology   (Canada)

^b Canadian Centre for Applied Research in Cancer Control   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cost effectiveness; economic evaluation; melanoma; oncology; review

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ALPHA INTERFERON; AMP 224; ANTINEOPLASTIC AGENT; BMS 936559; DABRAFENIB; DACARBAZINE; DARLEUKIN; GLYCOPROTEIN GP 100; IPILIMUMAB; MPDL 3280A; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PIDILIZUMAB; SELUMETINIB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADJUVANT THERAPY; ANALYTICAL EQUIPMENT; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE FREE INTERVAL; DRUG COST; DRUG MEGADOSE; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH SERVICE; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; INOPERABLE CANCER; LOW DRUG DOSE; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; OPERABLE CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SOCIAL SUPPORT; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT DURATION; WATCHFUL WAITING; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG DESIGN; ECONOMICS; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG DESIGN; HUMANS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 84924576163     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1017563     Document Type: Review

References (97)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63: 11-30
3. Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opin Investig Drugs 2012;21:557-68
4. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9
5. Vallejo-Torres J, Morris S, Kinge J, et al. Measuring current and future cost of skin cancer in England. J Public Health (Bangkok) 2014;36:140-8
6. Poirier V, Jones T, Ives A, et al. Skin cancer care in England. World Congress on Cancers of the Skin; 2014
7. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010;60:301-16
8. Melanoma of the skin. In: Edge S, Byrd D, Compton C, editors. AJCC cancer staging manual. Springer; New York, NY: 2010. p. 325-44
9. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012
10. Korn EL, Liu PY, Lee SJ, et al. Meta-Analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
11. Johnston K, Levy AR, Lorigan P, et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer 2012;48: 2175-82
12. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-Analysis. J Natl Cancer Inst 2010;102:493-501
13. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-Alpha for high-risk melanoma provide a worthwhile benefit?. A meta-Analysis of the randomised trials. Cancer Treat Rev 2003;29:241-52
14. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24
15. Maio M, Ascierto P, Testori A, et al. The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res 2012;31:91
16. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
17. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
18. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
19. Beale S, Dickson R, Bagust A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. Pharmacoeconomics 2013;31: 1121-9
20. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
21. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
22. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46
23. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol 2012;23(Suppl 8): viii15-21
24. Pretto F, Neri D. Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure. Pharmacol Ther 2013;139:405-11
25. National Institute for Health and Clinical Excellence. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 319, UK NHS; 2014
26. National Institute for Health and Clinical Excellence. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 268, UK NHS; 2012
27. Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer 2000;36:2344-52
28. Amdahl J, Wang A, Thabane M, et al. Cost effectiveness of trametinib as first-line treatment for BRAF V600 positive advanced or metastatic melanoma - a Canadian societal perspective. Value Health 2014; In Press
29. Delea T, Amdahl J, Wang A, et al. Cost-utility analysis of dabrafenib/trametinib combination for BRAF V600 mutation positive metastatic melanoma from the United Kingdom National Health Service Perspective. Value Health 2014; In Press
30. Shih V, Ten Ham R, Bui C, et al. BRAF targeted therapies for the treatment of metastatic melanoma: a cost-effectiveness analysis. Value Health 2014; In Press
31. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 2004;22:569-80
32. Covarelli P, Badolato M, Tomassini GM, et al. Sentinel lymph node biopsy under local anaesthesia versus general anaesthesia: reliability and cost-effectiveness analysis in 153 patients with malignant melanoma. In vivo 2012;26:315-18
33. Morton RL, Howard K, Thompson JF. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol 2009;16:929-40
34. Guillem V, Alvarez-Mon M, Camacho F, et al. Cost-effectiveness of interferon for high-risk (stage III) melanoma patients. Eur J Cancer Meeting 1999;abstract: 1513:S372
35. Agnese DM, Abdessalam SF, Burak WE Jr, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003;134:542-7
36. Alva M, Gay J, Sanchez Kobashi R. Cost effectiveness evaluation of vemurafenib, an orphan drug for BRAF mutant metastatic melanoma. Value Health 2012;15:A423
37. Cormier JN, Xing Y, Ding M, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 2007;25:2442-8
38. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 2004;7: 423-32
39. Hillner BE. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer 1998;34:S18-21
40. Lafuma A, Dreno B, Delaunay M, et al. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. Eur J Cancer 2001;37:369-75
41. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997;33:1373-9
42. Wilson LS, Reyes CM, Lu C, et al. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma. Melanoma Res 2002;12:607-17
43. Hillner BE, Agarwala S, Middleton MR. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. J Clin Oncol 2000;18:1474-80
44. Lee D, Winn B, Lebmeier M. Modelling the cost-effectiveness of ipilimumab for previously-treated, metastatic melanoma. Value Health 2012;15:A423
45. Radford M, Cortes P, Carrasco J. Cost-effectiveness of ipilimumab in previously treated patients for advanced melanoma in Portugal. Value Health 2013;16:A139
46. Muennig P. Cost-effectiveness analysis in health: a practical approach. 2nd edition. Jossey-Bass; San Francisco: 2014
47. Statistics Canada. Consumer Price Index, health and personal care, by province. 1-24-2014
48. National Institute of Statistics and Economic Studies. Consumer Price Index (monthly, all households, France, base 1998) - COICOP classification: 06. -Health. 10-7-2014
49. Office for National Statistics (UK). Consumer Price Indices - Tables. 7-14-2014
50. Statistics Portugal. Consumer Price Index. Healthcare expenditure. 10-7-2014
51. National Institute of Statistics (Spain). Consumer Price Index. National indices by subgroup. 11-7-2014
52. Bureau of Labor Statistics (US). Consumer Price Index - All Urban Customers -medical care. [Medical care]. 2014
53. Bank of Canada. 10-Year Currency Converter. 2014
54. Lafuma A, Grob JJ. Cost-effectiveness of interferon-Alpha2 as adjuvant therapy in malignant melanoma. Expert Opin Pharmacother 2003;4:343-9
55. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17
56. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58
57. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80
58. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-10
59. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-Adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002;20:1311-18
60. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50, 000-per-QALY threshold. N Engl J Med 2014;371:796-7
61. MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00094653
62. Rowen D, Brazier J, Young T, et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 2011;14:721-31
63. Aggerwal A, Sullivan R. Affordability of cancer care in the United Kingdom - Is it time to introduce user charges?. J Cancer Policy 2014;2:31-9
64. Beusterien KM, Szabo SM, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 2009;101:387-9
65. Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
66. Glasziou PP, Cole BF, Gelber RD, et al. Quality adjusted survival analysis with repeated quality of life measures. Stat Med 1998;17:1215-29
67. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-Analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
68. GlaxoSmithKline Clinical Study Register. BRF113220 Study summary report (Study 200226). 2014
69. National Institute for Health and Clinical Excellence. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma: NICE technology appraisal guidance 321 [abstract] National Institute for Health and Clinical Excellence. UK NHS 2014
70. NHS England. National Cancer Drugs Fund List. [3.0]; 2015
71. Eggermont A, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. Asia Pac J Clin Oncol 2014;10:175
72. Niebling MG, Wevers KP, Hoekstra HJ. The prognostic significance of BRAF mutation status in stage IIIB-C melanoma. Expert Rev Dermato 2013;8:127-9
73. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85
74. US Food and Drug Administration. FDA News Release: FDA approves Keytruda for advanced melanoma. 2014. Available from: www fda gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802 htm; serial online
75. Antoni RS, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients with melanoma. J Clin Oncol 2014;32:5s
76. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
77. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30
78. Ono Pharmaceutical Co. Human Anti-human PD-1 Monoclonal Antibody OPDIVO- Intravenous Infusion 20 mg/100 mg launches in Japan for Treatment of Unresectable Melanoma. 2014. Available from: www ono co jp/eng/news/pdf/sm-cn140902 pdf; serial online
79. Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics 2010;28:153-62
80. Chang C, Yim Y, Munakata J, et al. Comparative health care costs in patients with metastatic melanoma [abstract]. J Clin Oncol (ASCO Annual Meeting) 2014; 32(5s(Suppl):abstract 9007
81. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297:278-85
82. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66
83. Hersh EM, ODay SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011;29: 489-98
84. Ascierto PA. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Tumori 2013;99:302e-5e
85. GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01245062
86. A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00034827
87. MEK Inhibitor PD-325901 to treat advanced breast cancer, colon cancer, and Melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00147550
88. Randomised study to compare the efficacy of AZD6244 vs TMZ. Available from: https://clinicaltrials.gov/ct2/show/NCT00338130
89. A Trial of ABI-007 versus dacarbazine in previously untreated patients with metastatic malignant melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00864253
90. Safety, tolerability and efficacy study of the monoclonal antibody, CT-011, in patients with metastatic melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01435369
91. BMS-936558 (MDX-1106) In subjects with advanced/metastatic clear-cell renal cell carcinoma (RCC). Available from: https://clinicaltrials.gov/ct2/show/NCT01354431
92. A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafenib (Zelboraf-) or Vemurafenib plus cobimetinib in patients with previously untreated BRAFV600-mutation positive metastatic melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01656642
93. Multiple ascending dose (MDX1105-01) (Anti-PDL1). Available from: https://clinicaltrials.gov/ct2/show/NCT00729664
94. Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990/MK-3475-001/KEYNOTE-001). Available from: https://clinicaltrials.gov/ct2/show/NCT01295827
95. Study to assess the safety, tolerability, and pharmacokinetics of AMP-224 in patients with advanced cancer. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01352884
96. Clinical study phase II of L19IL2 in combination with dacarbazine in patients with metastatic melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01055522
97. An extended use study of safety and efficacy of oncoVEXGM-CSF in melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01368276